Schleifer is one of biopharma’s most colorful personalities, with his tendency to tell it like it is and his aversion to pulling punches. But for all the theatrics, the company he co-founded, Regeneron Pharmaceuticals, has done some serious science, bringing to market more than half a dozen drugs. (Much credit also goes to co-founder and chief scientist George Yancopoulos.) In 2021, the development of an antibody cocktail against Covid-19 earned Regeneron $6 billion and helped it garner national headlines. The company also landed an admirer in then-President Trump, who was famously treated with the therapy when he contracted Covid.